IPP Bureau
Glenmark Pharma gets VAI from FDA for Monroe facility
By IPP Bureau - November 27, 2025
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
EU greenlights Dupixent for chronic urticaria, offering new hope to patients
By IPP Bureau - November 27, 2025
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response
By IPP Bureau - November 27, 2025
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Valneva shifts French ops to Lyon
By IPP Bureau - November 27, 2025
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
Gavi and UNICEF ink agreement to slash malaria vaccine price
By IPP Bureau - November 27, 2025
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor
By IPP Bureau - November 27, 2025
Owlet’s push comes as parents demand smarter, more dependable nursery tech
Otsuka files FDA application for first-in-class ADHD drug
By IPP Bureau - November 27, 2025
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
NHS’s breakthrough leukaemia therapy set to transform lives in UK
By IPP Bureau - November 27, 2025
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks
By IPP Bureau - November 27, 2025
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Zydus receives FDA’s tentative approval for Empagliflozin and Linagliptin tablets
By IPP Bureau - November 27, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
By IPP Bureau - November 26, 2025
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Teva breaks ground with EU approval for two key bone disease biosimilars
By IPP Bureau - November 26, 2025
Bengaluru makes medical history with first robot-assisted deceased donor kidney transplant
By IPP Bureau - November 26, 2025
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
India becomes first country to approve STIMULAN Rapid Cure with antifungals
By IPP Bureau - November 26, 2025
Surgical site infections and antimicrobial resistance remain major challenges globally
Novartis scores FDA nod for game-changing SMA treatment
By IPP Bureau - November 26, 2025
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
